Corticosteroid Receptors in Cardiac Health and Disease
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG..
Nuclear receptors play a central role in both energy metabolism and cardiomyocyte death and survival in the heart. Recent evidence suggests they may also influence cardiomyocyte endowment. Although several members of the nuclear receptor family play key roles in heart maturation (including thyroid hormone receptors) and cardiac metabolism, here, the focus will be on the corticosteroid receptors, the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). The heart is an important target for the actions of corticosteroids, yet the homeostatic role of GR and MR in the healthy heart has been elusive. However, MR antagonists are important in the treatment of heart failure, a condition associated with mitochondrial dysfunction and energy failure in cardiomyocytes leading to mitochondria-initiated cardiomyocyte death (Ingwall and Weiss, Circ Res 95:135-145, 2014; Ingwall , Cardiovasc Res 81:412-419, 2009; Zhou and Tian , J Clin Invest 128:3716-3726, 2018). In contrast, animal studies suggest GR activation in cardiomyocytes has a cardioprotective role, including in heart failure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1390 |
|---|---|
| Enthalten in: |
Advances in experimental medicine and biology - 1390(2022) vom: 13., Seite 109-122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ivy, Jessica R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.09.2022 Date Revised 06.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-3-031-11836-4_6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346241006 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346241006 | ||
| 003 | DE-627 | ||
| 005 | 20240306232139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-3-031-11836-4_6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM346241006 | ||
| 035 | |a (NLM)36107315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ivy, Jessica R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corticosteroid Receptors in Cardiac Health and Disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.09.2022 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG. | ||
| 520 | |a Nuclear receptors play a central role in both energy metabolism and cardiomyocyte death and survival in the heart. Recent evidence suggests they may also influence cardiomyocyte endowment. Although several members of the nuclear receptor family play key roles in heart maturation (including thyroid hormone receptors) and cardiac metabolism, here, the focus will be on the corticosteroid receptors, the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). The heart is an important target for the actions of corticosteroids, yet the homeostatic role of GR and MR in the healthy heart has been elusive. However, MR antagonists are important in the treatment of heart failure, a condition associated with mitochondrial dysfunction and energy failure in cardiomyocytes leading to mitochondria-initiated cardiomyocyte death (Ingwall and Weiss, Circ Res 95:135-145, 2014; Ingwall , Cardiovasc Res 81:412-419, 2009; Zhou and Tian , J Clin Invest 128:3716-3726, 2018). In contrast, animal studies suggest GR activation in cardiomyocytes has a cardioprotective role, including in heart failure | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antenatal corticosteroids | |
| 650 | 4 | |a Cardiomyocyte | |
| 650 | 4 | |a Corticosteroid | |
| 650 | 4 | |a DOHAD (developmental origins of health and disease) | |
| 650 | 4 | |a Fetal programming | |
| 650 | 4 | |a Glucocorticoid | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Preterm birth | |
| 650 | 7 | |a Receptors, Glucocorticoid |2 NLM | |
| 650 | 7 | |a Receptors, Mineralocorticoid |2 NLM | |
| 650 | 7 | |a Receptors, Thyroid Hormone |2 NLM | |
| 700 | 1 | |a Gray, Gillian A |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, Megan C |e verfasserin |4 aut | |
| 700 | 1 | |a Denvir, Martin A |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Karen E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in experimental medicine and biology |d 1971 |g 1390(2022) vom: 13., Seite 109-122 |w (DE-627)NLM000012157 |x 0065-2598 |7 nnns |
| 773 | 1 | 8 | |g volume:1390 |g year:2022 |g day:13 |g pages:109-122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-3-031-11836-4_6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1390 |j 2022 |b 13 |h 109-122 | ||